Abstract：
In the1980s, radiolabeled cells helped understand the pathology of hemato-oncology. In the 1990s, preclinical trials evaluated radiolabeled immunotherapy with monoclonal antibodies (MoAbs) such as anti-CD20 agents labeled with Iodine-131 (Bexxar) or Yttrium-90 (Zevalin). Due to the safe and durable responses of radiolabeled MoAbs, the Food and Drug Administration approved these agents in the 2000s. Despite radioimmunotherapy\'s long journey, its application has recently decreased. This review will discuss the historical timeline of radioimmunotherapy, debate on advantages and difficulties, and explore trials. We will examine future directions of radioligand therapy in hemato-oncology, considering emerging molecules that may become the next theragnostic trend.
摘要：
在1980年代，放射性标记的细胞有助于了解血液肿瘤的病理学。在1990年代,临床前试验评估了使用单克隆抗体(MoAbs)的放射性标记免疫疗法,例如用碘-131(Bexxar)或钇-90(Zevalin)标记的抗CD20药物.由于放射性标记的Moabs的安全和持久的反应，美国食品和药物管理局在2000年代批准了这些药物。尽管放射免疫疗法的漫长旅程，其应用最近有所减少。这篇综述将讨论放射免疫疗法的历史时间表，关于优势和困难的辩论，探索试验。我们将研究血液肿瘤学中放射性配体治疗的未来方向，考虑可能成为下一个与治疗无关的趋势的新兴分子。
